Author: Leunar Miranda Leal

Hoofddorp, the Netherlands, 25 November 2021. IGEA Pharma N.V. (SIX: IGPH) receives an analyst vote. On Monday 22^nd the research house GBC AG (www.gbc-ag.de/) publishes its first coverage equity research on the Company and from now on, GBC analysts Matthias Greiffenbergerand Felix Haugg will cover the further development of Igea Pharma NV with continuous assessment.

Hoofddorp, the Netherlands, 04October 2021. IGEA Pharma N.V. (SIX: IGPH) today announced that GBCAG (www.gbc-ag.de/) will begin a full-coverage equity research on the Company.

Hoofddorp, the Netherlands, 30September 2021. IGEA Pharma N.V. (SIX: IGPH) todayannounced the disclosure of its half-2021 financials.

Hoofddorp, the Netherlands, 06Septmeber 2021. IGEA Pharma N.V. (SIX: IGPH) today announced the application of the listing prospectus to the SIX Swiss Exchange Ltd (“SIX”) for the admission of the New IGEA Pharma Shares to trading. The New Shares to be listed in accordance with the International Reporting Standard of SIX will be exclusively issued to current shareholders of Blue Sky Natural Resources Ltd.

Hoofddorp, the Netherlands, 2 August 2021. IGEA Pharma N.V. (SIX: IGPH) today announced revenue expectations over the next three years of CHF264 million globally, with an expected EBITDA margin in excess of 50% and expected net results of CHF126 million of the joint venture the Group will operate in the cannabis oil (CBD) market following the combination with Blue Sky Natural Resources Ltd (“BSNR”). The expected revenue stream from the joint venture of CHF63 million along with the additional EUR 4.5 million revenues from other segments will allow IGEA Pharma to be cash positive already by the end of 2022.

Hoofddorp, the Netherlands, 26 July 2021. IGEA Pharma N.V. (SIX: IGPH) today announced that the all equity offer (the “Offer”) to Blue Sky Natural Resources Ltd is now unconditional as to acceptances.